Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh Min Chen, Keunchil Park, Sang We Kim, Caicun Zhou, Wu Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crino, Eng Huat Tan, Tsu Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih Hsin Yang

Research output: Contribution to journalArticlepeer-review

841 Scopus citations

Fingerprint

Dive into the research topics of 'Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Nursing and Health Professions

Biochemistry, Genetics and Molecular Biology